HistoSonics, the developer of a non-invasive, novel sonic beam therapy, has raised $85 million in a financing led by Johnson & Johnson Innovation, to support its anticipated commercial launch, additional clinical trials, and to expand application development of Edison, the company’s novel histotripsy therapy platform, throughout the body.

Financing included participation from existing investors Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others.

Mike Blue, President and CEO of HistoSonics, commented: “These financings are an extraordinary vote of confidence in our team, as well as the novel platform and solution we have developed to transform experiences for patients and physicians who deal with the many challenges associated with significant disease, starting in the liver.”

The number of patients in the US who have primary liver tumours has increased 43% in the past 16 years and is expected to grow another 40% by 2030. HistoSonics recently submitted safety and efficacy data from its #HOPE4LIVER Clinical Trials to the US FDA and expects market authorization in 2023.

HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumours at sub-cellular levels. The company is currently focused on the development of its ‘Edison’ platform, combining advanced imaging with proprietary sensing technology to deliver personalized external beam treatments with unparalleled precision and control, and with the promise of reducing many of the side effects of conventional therapies.

For more information, visit: www.histosonics.com/